0.08Open0.08Pre Close0 Volume101 Open Interest10.00Strike Price0.00Turnover206.20%IV147.67%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.0930Delta0.0731Gamma50.88Leverage Ratio-0.0070Theta0.0002Rho4.73Eff Leverage0.0018Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet